Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2)
Phase 1
Not yet recruiting
- Conditions
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 125
- Registration Number
- NCT05928780
A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-06-29
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 88
- Registration Number
- NCT05924256
- Locations
- 🇨🇳
Dongmei Ji, Shanghai, China
A Cohort Study of Musculoskeletal Health in Patients With Breast Cancer During Aromatase Inhibitors Therapy
- First Posted Date
- 2023-06-27
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 870
- Registration Number
- NCT05921617
- Locations
- 🇨🇳
School of Nursing, Fudan University, Shanghai, Shanghai, China
Effects of Time-Restricted Fasting on the Postprandial Glycemic Responses
Not Applicable
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 36
- Registration Number
- NCT05913635
- Locations
- 🇨🇳
Shanghai Institute of Planned Parenthood Research Hospital, Shanghai, Shanghai, China
Axillary Surgery De-escalation After Neoadjuvant Therapy Using Dedicate Breast PET
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 100
- Registration Number
- NCT05914402
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai, Shanghai, China
Endostar Plus Toripalimab as Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Melanoma
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 43
- Registration Number
- NCT05907512
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Envafolimab Plus Docetaxel In Combination With or Without Trilaciclib Versus Docetaxel in Advanced NSCLC
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 132
- Registration Number
- NCT05910034
Long-term Prognosis for Non-functional Neuroendocrine Tumors of the Pancreatic Body and Tail ≤ 3cm
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 800
- Registration Number
- NCT05907824
- Locations
- 🇨🇳
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 548
- Registration Number
- NCT05909332
- Locations
- 🇨🇳
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China
🇨🇳West China Hospital of Sichuan University, Chengdu, Sichuan, China
🇨🇳The First Hospital of China Medical University, Shenyang, Liaoning, China
Circulating Tumor DNA Methylation Guided Postoperative Follow-up Strategy for Non-metastatic Colorectal Cancer
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 526
- Registration Number
- NCT05904665
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
© Copyright 2024. All Rights Reserved by MedPath